Trial Information

Summary: A Multicenter, Open-Label, Randomized, Phase II/III Study to Evaluate the Safety and Efficacy of Combretastatin A-4 Phosphate in Combination with Paclitaxel and Carboplatin in Comparison with Paclitaxel and Carboplatin Against Anaplastic Thyroid Carcinoma (OXC4T4)

Primary objective is to compare the antineoplastic efficacy of CA4P + paclitaxel + carboplatin+ with paclitaxel + carboplatin against ATC by measuring overall survival.

Secondary objectives are:

• To evaluate the safety and tolerability of the triple combination of CA4P + paclitaxel + carboplatin
• To assess specified objective events: tracheostomies, PEG tube placements, and weight loss

See www.hsc.wvu.edu/mbrcc/ctru/ for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:34:02 AM